Table 1.
Baseline Characteristics of Glioblastoma IDH Wild-Type WHO Grade 4 Cohort
| Characteristics and Measures | Newly Diagnosed (N = 29) | Recurrent Disease (N = 60) | All Subjects (N = 89) |
|---|---|---|---|
| Age, mean (SD), years | 62.8 (13.8) | 59.0 (11.0) | 60.2 (12.0) |
| Female, No. (%) | 9 (31.0) | 32 (53.3) | 41 (46.1) |
| Race/ethnicity, No. (%) | |||
| White | 25 (86.2) | 55 (91.7) | 80 (89.9) |
| Black/African American | 3 (10.3) | 1 (1.7) | 4 (4.5) |
| Asian | 1 (3.4) | 1 (1.7) | 2 (2.2) |
| Other/unknown | 0 (0) | 2 (3.3) | 2 (2.2) |
| Baseline KPS, n/N (%) | |||
| >70 | 15/22 (68.2) | 47/57 (82.5) | 62/79 (78.5) |
| <70 | 7/22 (31.8) | 10/57 (17.5) | 17/79 (21.5) |
| Reason for LITT, n/N (%) | |||
| Non-resectable lesion | 14/27 (51.9) | 25/59 (42.4) | 39/86 (45.3) |
| Minimally invasive procedure preferred | 11/27 (40.7) | 25/59 (42.4) | 36/86 (41.9) |
| Other | 3/27 (11.1) | 8/59 (13.6) | 11/86 (12.8) |
| MGMT promoter methylation, No. (%) | 5 (17.2) | 23 (38.3) | 28 (31.5) |
| Prior therapy (not mutually exclusive) | |||
| LITT ablation | – | 4 (6.7) | 4 (4.5) |
| Resection | – | 53 (88.3) | 53 (59.6) |
| Chemotherapy | – | 54 (90.0) | 54 (60.7) |
| Radiation (not mutually exclusive) | – | 52 (86.7) | 52 (58.4) |
| SRS | – | 8 (13.3) | 8 (9.0) |
| Whole-brain RT | – | 7 (11.7) | 7 (7.9) |
| Local | – | 38 (63.3) | 38 (42.7) |
| Procedural EOA (surgeon estimate), n/N (%) | |||
| 100 | 2/27 (7) | 18/58 (31) | 20/85 (24) |
| 91-99 | 13/27 (48) | 32/58 (55) | 45/85 (53) |
| 51-90 | 10/27 (37) | 8/58 (14) | 18/85 (21) |
| Deep seated lesion, n/N (%) | 20/34 (58.8) | 17/64 (26.6) | 37/98 (37.8) |
| Lesion volume <3 cc, n/N (%) | 15/31 (48.4) | 20/51 (39.2) | 35/82 (42.7) |
| Lesion volume >3 cc, n/N (%) | 16/31 (51.6) | 31/1 (60.8) | 47/82 (57.3) |
Abbreviations: EOA, extent of ablation; IDH, isocitrate dehydrogenase; KPS, Karnofsky Performance Scale; LITT, laser interstitial thermal therapy; RT, radiotherapy; SRS, stereotactic radiosurgery.